Fate Therapeutics, Inc. (FATE): Price and Financial Metrics


Fate Therapeutics, Inc. (FATE): $20.91

0.57 (+2.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FATE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FATE POWR Grades

  • Value is the dimension where FATE ranks best; there it ranks ahead of 60.77% of US stocks.
  • The strongest trend for FATE is in Growth, which has been heading down over the past 179 days.
  • FATE ranks lowest in Momentum; there it ranks in the 4th percentile.

FATE Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FATE is 0.13 -- better than only 13.97% of US stocks.
  • Of note is the ratio of FATE THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 8.72% of US stocks have a lower such ratio.
  • With a price/sales ratio of 27.12, FATE THERAPEUTICS INC has a higher such ratio than 95.28% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to FATE THERAPEUTICS INC, a group of peers worth examining would be IGMS, RLAY, NTLA, CCCC, and ARVN.
  • FATE's SEC filings can be seen here. And to visit FATE THERAPEUTICS INC's official web site, go to www.fatetherapeutics.com.

FATE Valuation Summary

  • In comparison to the median Healthcare stock, FATE's price/earnings ratio is 128.45% lower, now standing at -6.6.
  • Over the past 111 months, FATE's price/sales ratio has gone down 37.3.

Below are key valuation metrics over time for FATE.

Stock Date P/S P/B P/E EV/EBIT
FATE 2022-11-25 27.9 3.7 -6.6 -6.6
FATE 2022-11-23 27.7 3.7 -6.5 -6.5
FATE 2022-11-22 27.5 3.7 -6.5 -6.5
FATE 2022-11-21 27.7 3.7 -6.5 -6.5
FATE 2022-11-18 28.0 3.7 -6.6 -6.6
FATE 2022-11-17 28.3 3.8 -6.6 -6.7

FATE Growth Metrics

    Its 5 year revenue growth rate is now at 139.96%.
  • Its 4 year price growth rate is now at 551.29%.
  • The 3 year net income to common stockholders growth rate now stands at -222.27%.
Over the past 52 months, FATE's revenue has gone up $64,907,000.

The table below shows FATE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 69.013 -243.112 -293.979
2022-06-30 68.257 -221.44 -253.724
2022-03-31 63.12 -200.387 -232.752
2021-12-31 55.846 -162.87 -212.151
2021-09-30 54.675 -113.241 -196.641
2021-06-30 48.008 -110.599 -212.017

FATE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FATE has a Quality Grade of D, ranking ahead of 19.68% of graded US stocks.
  • FATE's asset turnover comes in at 0.058 -- ranking 313th of 680 Pharmaceutical Products stocks.
  • RMTI, SYBX, and PTE are the stocks whose asset turnover ratios are most correlated with FATE.

The table below shows FATE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.058 1 -0.324
2021-03-31 0.054 1 -0.384
2020-12-31 0.057 1 -0.550
2020-09-30 0.039 1 -0.586
2020-06-30 0.033 1 -0.572
2020-03-31 0.036 1 -0.625

FATE Price Target

For more insight on analysts targets of FATE, see our FATE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $109.83 Average Broker Recommendation 1.47 (Moderate Buy)

FATE Stock Price Chart Interactive Chart >

Price chart for FATE

FATE Price/Volume Stats

Current price $20.91 52-week high $66.56
Prev. close $20.34 52-week low $17.10
Day low $19.48 Volume 1,366,200
Day high $20.93 Avg. volume 1,411,859
50-day MA $20.87 Dividend yield N/A
200-day MA $27.63 Market Cap 2.03B

Fate Therapeutics, Inc. (FATE) Company Bio


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. The company was founded in 2007 and is based in San Diego, California.


FATE Latest News Stream


Event/Time News Detail
Loading, please wait...

FATE Latest Social Stream


Loading social stream, please wait...

View Full FATE Social Stream

Latest FATE News From Around the Web

Below are the latest news stories about FATE THERAPEUTICS INC that investors may wish to consider to help them evaluate FATE as an investment opportunity.

Have you been able to find a good deal on Fate Therapeutics Inc.’s shares?

The share price of Fate Therapeutics Inc. (NASDAQ:FATE) fell to $19.55 per share on Tuesday from $19.64. While Fate Therapeutics Inc. has underperformed by -0.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FATE fell by -62.73%, with highs and lows ranging from $66.56 to $17.10, […]

US Post News | November 23, 2022

Fate Therapeutics (FATE) Gets a Buy from H.C. Wainwright

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Fate Therapeutics (FATE - Research Report), with a price target of $115.00. The company's shares closed last Friday at $19.87.Burns covers the Healthcare sector, focusing on stocks such as MacroGenics, Neoleukin Therapeutics, and Y-Mabs Therapeutics. According to TipRanks, Burns has an average return of -24.1% and a 22.68% success rate on recommended stocks. In addition to H.C. Wainwright, Fate Therapeutics also received a Buy from Citigroup's Yigal Nochomovitz in a report issued on November 15. However, on November 14, Needham maintained a Hold rating on Fate Therapeutics (NASDAQ: FATE).

Brian Anderson on TipRanks | November 21, 2022

Investing in Fate Therapeutics Inc. (FATE) might be an excellent idea, but the stock is currently overvalued/undervalued

The share price of Fate Therapeutics Inc. (NASDAQ:FATE) rose to $22.28 per share on Tuesday from $22.16. While Fate Therapeutics Inc. has overperformed by 0.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FATE fell by -58.53%, with highs and lows ranging from $66.56 to $17.10, […]

US Post News | November 16, 2022

Fate Therapeutics: Promising Potential, Agonizingly Slow Progress (NASDAQ:FATE)

Fate Therapeutics is an industry leader in small molecules-induced pluripotency. Find out why FATE is a risky investment where a small pilot may be warranted.

Seeking Alpha | November 16, 2022

Fate Therapeutics: Added To ''Bio Boom'' Speculative Portfolio (FATE)

Fate Therapeutics is a leader in off-the-shelf cancer immunotherapies that have the potential to revolutionize the way we treat cancer. Click here to read why FATE is a Buy.

Seeking Alpha | November 15, 2022

Read More 'FATE' Stories Here

FATE Price Returns

1-mo 7.51%
3-mo -21.74%
6-mo -4.95%
1-year -56.44%
3-year 47.25%
5-year 401.44%
YTD -64.26%
2021 -35.65%
2020 364.64%
2019 52.53%
2018 109.98%
2017 143.43%

Continue Researching FATE

Here are a few links from around the web to help you further your research on Fate Therapeutics Inc's stock as an investment opportunity:

Fate Therapeutics Inc (FATE) Stock Price | Nasdaq
Fate Therapeutics Inc (FATE) Stock Quote, History and News - Yahoo Finance
Fate Therapeutics Inc (FATE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6067 seconds.